Hivary Sahar, Fatahinia Mahnaz, Halvaeezadeh Marzieh, Mahmoudabadi Ali Zarei
Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Iran J Microbiol. 2019 Dec;11(6):510-519.
Black strains including, and , are the most cause of otomycosis with worldwide distribution. Although, amphotericin B was a Gold standard for the treatment of invasive fungal infection for several decades, it gradually replaced by fluconazole and /or voriconazole. Moreover, luliconazole, appears to offer the best potential for activity against black strains. The aim of the present study was to compare the activity luliconazole, with commonly used antifungals against clinical and environmental strains of black .
Sixty seven (37 clinical and 30 environmental) strains of black were identified using morphological and molecular technique (β-Tubulin gene). In addition, antifungal susceptibility test was applied according to CLSI M38 A2. The results were reported as minimum inhibitory concentration (MIC) or minimum effective concentration (MEC) range, MIC or MEC, MIC or MEC and MIC geometric (GM) or MECGM.
was the common isolate followed by, in both clinical and environmental strains. The lowest MIC range, MIC, MIC, and MICGM was attributed to luliconazole in clinical strains. The highest resistant rate was found in amphotericin B for both clinical (86.5%) and environmental (96.7%) strains whereas 54.1% of clinical and 30% of environmental isolates were resistant to caspofungin. Clinical strains of were more sensitive to voriconazole (86.7%) than environmental strains (70.3%). On the other hand, 83.8% of clinical and 70% of environmental isolates were resistant to posaconazole.
Luliconazole versus amphotericin B, voriconazole, posaconazole and caspofungin is a potent antifungal for Nigri complex. The extremely antifungal efficacy against black strains of luliconazole, is different from those of other used antifungals.
包括[具体菌株1]和[具体菌株2]在内的黑色真菌菌株是全球范围内耳真菌病的最主要病因。尽管几十年来两性霉素B一直是治疗侵袭性真菌感染的金标准，但它逐渐被氟康唑和/或伏立康唑所取代。此外，卢立康唑似乎对黑色真菌菌株具有最佳的抗真菌活性潜力。本研究的目的是比较卢立康唑与常用抗真菌药物对临床和环境来源的黑色真菌菌株的抗真菌活性。
使用形态学和分子技术（β-微管蛋白基因）鉴定了67株（37株临床菌株和30株环境菌株）黑色真菌。此外，根据CLSI M38 A2进行抗真菌药敏试验。结果以最低抑菌浓度（MIC）或最低有效浓度（MEC）范围、MIC或MEC、MIC或MEC以及MIC几何均值（GM）或MECGM报告。
在临床和环境菌株中，[具体菌株3]是最常见的分离菌株，其次是[具体菌株4]。临床菌株中，最低MIC范围、MIC、MIC和MICGM均归因于卢立康唑。两性霉素B对临床菌株（86.5%）和环境菌株（96.7%）的耐药率最高，而54.1%的临床分离株和30%的环境分离株对卡泊芬净耐药。临床来源的[具体菌株5]对伏立康唑（86.7%）的敏感性高于环境菌株（70.3%）。另一方面，83.8%的临床分离株和70%的环境分离株对泊沙康唑耐药。
与两性霉素B、伏立康唑、泊沙康唑和卡泊芬净相比，卢立康唑是一种对黑色真菌复合体有效的抗真菌药物。卢立康唑对黑色真菌菌株具有极高的抗真菌疗效，这与其他使用的抗真菌药物不同。
